Pharmaceuticals company Indoco Remedies announced Q1FY26 results Revenues of Indoco Remedies are at Rs 3,838 million, as against Rs 3,411 million, in previous quarter, registering 12.5% revenue growth. EBIDTA for the quarter is at Rs 148 million, compared to Rs 35 million in the previous quarter. Aditi Panandikar, Managing Director, Indoco Remedies, said: “Our 12.5% revenue growth this quarter over last quarter reflects the resilience of our teams, operational excellence and robust strategy. We are confident of sustaining this momentum and making a turnaround going ahead.” Result PDF
Pharmaceuticals company Indoco Remedies announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: During the fourth quarter of FY 2024-25, revenues of Indoco Remedies are at Rs 3,411 million, as against Rs 4,351 million, same quarter last year. EBIDTA for the quarter is at Rs 35 million, compared to Rs 574 million, same quarter last year. FY25 Financial Highlights: For the year, revenues are at Rs 14,948 million, as against Rs 17,620 million, same period last year. EBIDTA to net sales for the period is 8.6 % at Rs 1,280 million, compared to 14.6 % at Rs 2,580 million, same period last year. Profit After Tax are at Rs -87 million, compared to Rs 1,166 million, same period last year. Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “While this has been a challenging year for Indoco, there are several optimistic triggers which gives us confidence for a better future, both in the short as well as long term.” Result PDF